Thanks to patent expirations of several key therapies, the Human
Immunodeficiency Virus (HIV) treatment market value will increase at a
slow pace in the coming years, from $14.3 billion in 2012 to $16.3
billion by 2019, at a Compound Annual Growth Rate (CAGR) of 1.9%.

According to the company's latest report, the first-line antiretroviral
therapies Atripla and Truvada will lose patent protection during the
forecast period, which will hurt their markets in Europe and Canada.

<>
Angel Wong, report analyst, says: Despite such patent losses, a number
of drugs will enter the HIV market by 2019. Among these new entrants,
572-Trii is expected to perform the strongest commercially and will
compete with Atripla following its approval. However, these drugs will
not offset the impact of generic erosion.

Currently, the HIV pipeline is strong and displays a high degree of
novelty and diversity, according to the authors. The pipeline also
consists of therapies that address the unmet needs of drug resistance
and toxicity. These drugs are Nucleoside Reverse Transcriptase Inhibitor
(NRTI) apricitabine, censavudine and elvucitabine, which deal with the
issue of NRTI resistance.

Another candidate in the HIV pipeline, which is a new pro-drug of
tenofovir, called tenofovir alafenamide, has also demonstrated a more
favorable toxicity profile than its predecessor Viread.

Wong says: Despite the promising outlook, the HIV pipeline has suffered
from high attrition rates in recent years, particularly with vaccines.
None of these have been approved for the treatment of HIV. These
failures reflect an urgent need for a more thorough understanding of
immune response against HIV and more streamlined clinical trial designs,
the analyst concludes.

This report analyzes treatment usage patterns, drug types available and
pipeline and market forecasts across indications for HIV. Countries
covered in this report include the US, France, Germany, Italy, Spain,
the UK, Japan and Canada.

This report was built using data and information sourced from
proprietary databases, primary and secondary research, and in-house
analysis conducted by a team of industry experts.